Cited by 413Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, Yoh, Kiyotaka, Zhou, Jian-Ying, Shi, Xiaojin, Webster, Alan, Jiang, Haiyi, Mok, Tony S K·2015·The Lancet Oncology

DOI 10.1016/s1470-2045(15)00121-7

Open this paper in CoChat — free account

Abstract

Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib.Methods The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in 11 countries in Europe and the Asia-Pacific region. Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). Participants were randomly assigned (1:1) by central block randomisation to oral gefitinib 250 mg or placebo once daily in tablet form; randomisation did not include stratification factors. All patients also received the platinum-based doublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle. After completion of a maximum of six chemotherapy cycles, patients continued their randomly assigned treatment until disease progression or another discontinuation criterion was met. All study investigators and participants were masked to treatment allocation. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The study has completed enrolment, but patients are still in follow-up for overall survival. This trial is registered with ClinicalTrials.gov, number NCT01544179.Findings Between March 29, 2012, and Dec 20, 2013, 265 patients were randomly assigned: 133 to the gefitinib group and 132 to the placebo group. At the time of data cutoff (May 5, 2014), 98 (74%) patients had disease progression in the gefitinib group compared with 107 (81%) in the placebo group (hazard ratio 0·86, 95% CI 0·65-1·13; p=0·27; median progression-free survival 5·4 months in both groups [95% CI 4·5-5·7 in the gefitinib group and 4·6-5·5 in the placebo group]). The most common adverse events of any grade were nausea (85 [64%] of 132 patients in the gefitinib group and 81 [61%] of 132 patients in the placebo group) and decreased appetite (65 [49%] and 45 [34%]). The most common adverse events of grade 3 or worse were anaemia (11 [8%] of 132 patients in the gefitinib group and five [4%] of 132 patients in the placebo group) and neutropenia (nine [7%] and seven [5%]). 37 (28%) of 132 patients in the gefitinib group and 28 (21%) of 132 patients in the placebo group reported serious adverse events.Interpretation Continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong progression-free survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment. Platinum-based doublet chemotherapy remains the standard of care in this setting.Funding AstraZeneca.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)00121-7

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Self-citation
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citation
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citation

Show all 30 references

Sorted by citations

Items 201–300 of 411

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective
Lai-Kwon, J. E., Tiu, C., Pal, A., Khurana, S., & Minchom, A. R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103225 · Cited by 16
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
Guan, Y., Li, M., He, Q. W., Li, M., & Luo, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80635 · Cited by 15
Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges
Xia, B., Zhang, S., & Ma, S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.67 · Cited by 15
“For patients with active EGFR mutations, TKIs produced high response rates up to 75% and improved progression-free survival (PFS) to 9–13 months as compared with chemotherapy in randomized trials (4,9-11).”
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Arriola, E., Gómez, R. G., Díz, P., Majem, M., Aguillo, M. M., Valdivia, J., Paredes, A., Sánchez-Torres, J. M., Muñoz, S. P., Barneto, I., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4004-7 · Cited by 17
“The phase III IMPRESS study showed that continuation of gefitinib in combination with platinum-based doublet chemotherapy after disease progression on first-line gefitinib did not prolong PFS compared with chemotherapy alone in patients with NSCLC carrying EGFR mutations [38].”
BackgroundSelf-citation
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Yoo, K. H., Lee, S. J., Cho, J., Lee, K. H., Park, K. U., Kim, K. H., Cho, E. K., Choi, Y. H., Kim, H. R., Kim, H., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.324 · Cited by 15
Self-citation
Genotoxicity and repair capability of Mus musculus DNA following the oral exposure to Tramadol
Ali, T., Rafiq, M., Mubarik, M. S., Zahoor, M. K., Asad, F., Yaqoob, S., Ahmad, S., & Qamar, S. (2019) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2019.03.008 · Cited by 15
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
Zhong, H., Zhang, X., Tian, P., Chu, T., Guo, Q., Yu, X., Yu, Z., Li, Y., Chen, L., Liu, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006887 · Cited by 17
Self-citation
Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro
Xie, B., Sun, L., Cheng, Y., Zhou, J., Zheng, J., & Zhang, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s165831 · Cited by 14
“However, the irradiation induces irreversible apoptosis in EGFR-mutated NSCLC, but not in WT EGFR NSCLC, further confirming the enhanced radiosensitivity of EGFR-mutated NSCLC. Mechanistically, EGFR mutations may promote cell apoptosis via the Bcl-2/Bax signaling pathway, as shown by irradiation-suppressed Bcl-2 expre…”
Self-citation
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee, C., Sharma, S., Miao, E., Mensah, C., Sullivan, K. M., & Seetharamu, N. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s258444 · Cited by 15
Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Wang, Y., Wang, M., Wang, Q., Geng, Z., & Sun, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14707 · Cited by 15
“As a result, 25 RCTs with 13,436 patients were included for the present study [17-41].”
Background
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
Spigel, D. R., Rubin, M. S., Gian, V. G., Shipley, D. L., Burris, H. A., Kosloff, R. A., Shih, K. C., Quinn, R., Greco, F. A., & Hainsworth, J. D. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.09.007 · Cited by 14
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
Zhang, Z., Zeng, K., Zhao, S., Zhao, Y., Hou, X., Luo, F., Lu, F., Zhang, Y., Zhou, T., Ma, Y., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919891652 · Cited by 15
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
“There was a trend toward shorter OS when gefitinib was continued in conjunction with chemotherapy.[57] In LUX‐Lung 7 trial afatinib and gefitinib were continued beyond RECIST progression and median time to failure (TTF) was significantly prolonged in afatinib versus gefitinib (median TTF 13.”
Background
Update in Lung Cancer 2015
Spira, A. E., Halmos, B., & Powell, C. A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0898up · Cited by 13
Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms
Proto, C., Russo, G. L., Corrao, G., Ganzinelli, M., Facchinetti, F., Minari, R., Tiseo, M., & Garassino, M. C. (2017) · Tumori Journal · doi:10.5301/tj.5000663 · Cited by 14
“After progression, no benefit was observed with the combination of gefitinib and chemotherapy, supporting discontinuation of EGFR TKI in progressing patients at the start of second-line chemotherapy (90).”
Background
Saudi lung cancer management guidelines 2017
Jazieh, A. R., Kattan, K. A., Bamousa, A., Olayan, A. A., Abdelwarith, A., Ansari, J., Al-Twairqi, A., Alfayea, T. M., Saleh, K. A., Husaini, H. A., et al. (2017) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_92_17 · Cited by 12
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment
Su, P., Tsai, J., Yang, S., Wu, Y., Tseng, Y., Chang, C., Yen, Y., Lin, C.-Y., Lin, C., Wang, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.014 · Cited by 13
Self-citation
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Xu, J., Yang, H., Jin, B., Lou, Y., Zhang, Y., Zhang, X., Zhong, H., Wang, H., Wu, D., & Han, B. (2016) · Scientific Reports · doi:10.1038/srep36371 · Cited by 13
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Favorito, V., Ricciotti, I., Giglio, A. D., Fabbri, L., Seminerio, R., Federico, A. D., Gariazzo, E., Costabile, S., & Metro, G. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2331139 · Cited by 13
“In the phase III IMPRESS trial, adding chemotherapy to gefitinib after progression showed no advantage in outcome parameters [101,102].”
Background
Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence
Werner, R. S., Steinmann, N., Decaluwé, H., Date, H., Ruysscher, D. D., & Opitz, I. (2024) · European Respiratory Review · doi:10.1183/16000617.0200-2023 · Cited by 12
“However, in contrast, the IMPRESS phase 3 study assessed the efficacy of continuing gefitinib with platinum-based chemotherapy for gefitinib-resistant NSCLC and did not find significantly prolonged PFS when compared to platinum-based chemotherapy alone [38].”
Background
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
González-Larriba, J. L., Lázaro-Quintela, M., Cobo, M., Dómine, M., Majem, M., & García‐Campelo, R. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.03 · Cited by 12
“However, the phase III IMPRESS study showed no significant improvement in PFS and OS with continued use of gefitinib plus pemetrexed/cisplatin doublet chemotherapy compared with chemotherapy alone in 265 EGFR mutation-positive patients who progressed on first-line treatment with EGFR-TKIs (60).”
Background
Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
Koyyala, V. P. B., Batra, U., Jain, P., Sharma, M., Goyal, P., Medisetty, P., Jajodia, A., & Maheshwari, U. (2018) · Lung India · doi:10.4103/lungindia.lungindia_451_17 · Cited by 12
“more viable, as seen in IMPRESS trial, such patients have not shown prolongation of PFS and overall survival with continuation of gefitinib after progression.[25] Moreover, with the introduction of third-generation EGFR TKI that works effectively even in the presence of T790M”
Method
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Carter, C. A., Oronsky, B. T., Caroen, S. Z., Scicinski, J. J., Cabrales, P., Degesys, A., & Brzezniak, C. E. (2016) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2016.04.007 · Cited by 12
“While the literature describes retreatment with TKI inhibitors after a drug-free interval and/or treatment past RECIST-defined progression, no clear evidence supports these strategies [17]; in fact, recent data from the IMPRESS trial [18] (A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Vers…”
Result
Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
Steen, N. V. D., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C. D., Germonpré, P. R., Giovannetti, E., Peters, G. J., & Pauwels, P. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i6.425 · Cited by 12
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations
Osoegawa, A., Takumi, Y., Hashimoto, T., Nakatsuji, S., Hori, M., Sakai, M., Karashima, T., Abe, M., Miyawaki, M., & Sugio, K. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01337-8 · Cited by 11
Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
Tudor, R., D’Silva, A., Tremblay, A., MacEachern, P. R., Morris, D. G., Brenner, D. R., Kopciuk, K. A., & Bebb, D. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181867 · Cited by 11
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
Ding, J., Ding, X., & Leng, Z. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2170879 · Cited by 11
“4 months of median progression-free survival (mPFS) [5,6].”
Background
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
Rossi, A., Salvia, A. L., & Maïo, M. D. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1290526 · Cited by 11
“ond-line treatment of gefitinib-resistant EGFR-mutated NSCLC patients [48].”
Background
Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells
Yang, S., Nan, P., Li, C., Lin, F., Li, H., Wang, T., Zhou, C., Zhang, X., Meng, X.-T., Qian, H., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.110 · Cited by 11
Value of interim 18F-FDG PET/CT for predicting progression-free survival in stage ⅢB/IV EGFR-mutant non–small-cell lung cancer patients with EGFR-TKI therapy
Shao, D., Cheng, Y., Yuan, Z., Jiang, B., & Wang, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.020 · Cited by 11
Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation
Blanc‐Durand, F., Florescu, M., Tehfe, M. A., Routy, B., Alameddine, R. S., Tran‐Thanh, D., & Blais, N. (2021) · Current Oncology · doi:10.3390/curroncol28020102 · Cited by 12
Correction: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Xu, J., Yang, H., Jin, B., Lou, Y., Zhang, Y., Zhang, X., Zhong, H., Wang, H., Wu, D., & Han, B. (2016) · Scientific Reports · doi:10.1038/srep38270 · Cited by 11
Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer
Kazaz, S. N., & Öztop, İ. (2017) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2017.16042 · Cited by 10
Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
Yi, X.-F., Song, J., Gao, R.-L., Sun, L., Wu, Z., Zhang, S., Huang, L., Ma, J., & Han, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863666 · Cited by 10
Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
Zhang, M., Guo, H., Zhao, S., Wang, Y., Yang, M., Yu, J., Yan, Y., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9503 · Cited by 10
Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer
Pakkala, S., & Ramalingam, S. S. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.003 · Cited by 10
Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review
Simons, M., Ramaekers, B. L. T., Peeters, A., Mankor, J. M., Paats, M. S., Aerts, J. G. J. V., van Harten, W. H., Retèl, V. P., & Joore, M. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103035 · Cited by 10
The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018
Haslam, A., Gill, J., Crain, T., Herrera-Perez, D., Chen, E. Y.-S., Hilal, T., Kim, M. S., & Prasad, V. K. (2021) · BMC Cancer · doi:10.1186/s12885-021-08632-8 · Cited by 10
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Westerink, L., Nicolai, J. L. J., Samuelsen, C. H., Smit, H. J. M., Postmus, P. E., Griebsch, I., & Postma, M. J. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01186-9 · Cited by 10
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Chen, H., Tu, H., Hu, Y., Fan, Y., Wu, G., Cang, S., Yang, Y., Yang, N., Ma, R., Jin, G., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01656-0 · Cited by 9
“The IMPRESS study indicated that continuing gefitinib upon gefitinib progression did not improve PFS and OS in patients who received platinum-based doublet chemotherapy as subsequent line of treatment [28, 29].”
Self-citation
EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC
Zhou, Z., Chen, S. E., Zhao, J., Du, X., Yin, H., Zhou, C., Hu, H., Yu, Y., Zhu, Y., & Yao, H. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102199 · Cited by 10
“EGFR TKIs show strong efficacy in EGFR-mutant NSCLC, and ongoing studies are optimizing outcomes through first-to third-generation TKIs and their combinations with chemotherapy 50,51 or ICIs.”
Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
Noda, S., & Kanda, S. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1164603 · Cited by 10
“The IMPRESS study was a randomized, placebo-controlled, phase III study to establish whether patients with advanced EGFR-mutant NSCLC who developed acquired resistance to first-line gefitinib might benefit from the continuation of gefitinib in addition to platinum-doublet chemotherapy [69].”
Method
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
Remón, J., & Besse, B. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000081 · Cited by 9
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials
Qiao, L., Wang, J., Long, G., & Jiang, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s128187 · Cited by 9
“Meanwhile, pemetrexed has less side effects than other TKIs and a RCT has also proven it to be effective as maintenance therapy after first-line PCT in non-squamous NSCLC.23 Also, as a second-line, pemetrexed had significantly better clinical efficacy in patients with susceptible EGFR mutations after progression of fi…”
BackgroundInfluentialSelf-citation
Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
Skrzypski, M. T., Szymanowska-Narloch, A., & Dziadziuszko, R. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.70116 · Cited by 9
Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
Lengel, H. B., Zheng, J., Tan, K. S., Liu, C. C., Park, B. J., Rocco, G., Adusumilli, P. S., Molena, D., Yu, H. A., Riely, G. J., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.056 · Cited by 9
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
Patil, T., Staley, A. W., Nie, Y., Sakamoto, M., Stalker, M., Jurica, J. M., Koehler, K., Cass, A., Kuykendall, H., Schmitt, E., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100637 · Cited by 9
“The ef ﬁ cacy of continuing TKIs with chemotherapy post-progression remains under debate 35 – 37 and is being evaluated prospectively through the ongoing COMPEL (NCT04765059) and Lung-MAP (NCT05364645) clinical trials.”
Method
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression
Moiseenko, F. V., Moiseyenko, V. M., Алексахина, С. Н., Chubenko, V. A., Волков, Н. М., Kozyreva, K. S., Kramchaninov, M. M., Zhuravlev, A. S., Shelekhova, K. V., Ivantsov, A. O., et al. (2016) · Oncology Research and Treatment · doi:10.1159/000449024 · Cited by 9
18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients
Bai, L., Guo, C., Wang, J., Liu, X., Li, Y., Li, M., Guo, Y., & Duan, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s113832 · Cited by 9
“Therefore, it was risky to use p53 and ERCC1 as the biomarkers for chemotherapy resistance in NSCLC, not to mention using SUV max and TLG of 18 F-FDG PET/CT to represent p53 and ERCC1 for evaluating the effect of the treatment.”
InfluentialSelf-citation
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis
Zhang, Y., Miao, S., Wang, F., Fang, W., Chen, G., Chen, X., Yan, F., Huang, X., Wu, M., Huang, Y., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.08 · Cited by 10
Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
Qiu, X., Yuan, H., & Sima, B. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12928 · Cited by 9
Mixed response to osimertinib and the beneficial effects of additional local therapy
Shinno, Y., Goto, Y., Sato, J., Morita, R., Matsumoto, Y., Murakami, S., Kanda, S., Horinouchi, H., Fujiwara, Y., Yamamoto, N., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12991 · Cited by 9
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect
Paolini, D., Tiseo, M., Demma, F., Furneri, G., Dionisi, M., Akkermans, M., & Marchetti, A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.012 · Cited by 9
Precision medicine and actionable alterations in lung cancer: A single institution experience
Mambetsariev, I., Wang, Y., Chen, C., Nadaf, S., Pharaon, R. R., Fricke, J., Amanam, I. U., Amini, A., Bild, A. H., Chu, P. G., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228188 · Cited by 9
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
Tozuka, T., Noro, R., Yoshida, K., Takahashi, S., Hirao, M., Matsuda, K., Kato, Y. X., Nakamichi, S., Takeuchi, S., Matsumoto, M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100668 · Cited by 11
“…ge ﬁ tinib resistance in patients with EGFR -mutant NSCLC revealed that the addition of EGFR TKI to chemotherapy did not have any survival bene ﬁ t. 47 Nevertheless, osimertinib plus MET-TKI such as tepoti-nib had meaningful overall response rates and clinical outcomes for patients with EGFR…”
Background
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
Cerbone, L., Benítez, J. C., Planchard, D., & Genova, C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888928 · Cited by 8
“depends on histology shift, platinum-based chemotherapy should be considered, based on the specific histotype involved; for instance, in case of SCLC transformation, standard chemotherapy with platinum-etoposide should be considered [69].”
Background
Cross-talk between next generation sequencing methodologies to identify genomic signatures of esophageal cancer
Verma, R., Sattar, R. S. A., Nimisha, Apurva, A., Kumar, A., Sharma, A. K., Sumi, M. P., Ahmad, E., Ali, A., Mahajan, B., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103348 · Cited by 8
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach
Melosky, B. L., Popat, S., & Gandara, D. R. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.019 · Cited by 8
“Anecdotal observational studies have supported this concept.47,48 To evaluate this concept prospectively, the IMPRESS study (gefitinib plus chemotherapy vs. placebo plus chemotherapy in EGFR-mutation-positive nonesmall-cell lung cancer after progression on first-line gefitinib) randomized patients progressing with EGF…”
MethodInfluential
Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial
Ito, K., & Hataji, O. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.52 · Cited by 7
“IMPRESS (37,38) III Gefitinib + CDDP + PEM; CDDP + PEM 133; 132 5.”
BackgroundInfluential
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges
Tfayli, A., & Mohty, R. (2020) · Tumori Journal · doi:10.1177/0300891620968138 · Cited by 8
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma
Riudavets, M., Bosch‐Barrera, J., Cabezón‐Gutiérrez, L., Taín, P. D., Hernández, A., Alonso, M. D., Blanco, R., Gálvez, E., Insa, A., Mielgo-Rubio, X., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02661-2 · Cited by 8
Self-citation
Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies
Ho, V. W.-T., Tan, H. Y., Wang, N., & Feng, Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82513 · Cited by 8
Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis
Xinmin, Z., Wan, X., Xu, J. H., Wang, H., Chen, H., Zeng, Q., Zhang, W., & Zhao, B. (2020) · Aging · doi:10.18632/aging.103066 · Cited by 8
“Ten studies [14, 26, 31, 34, 35, 38, 39, 42, 43, 46] reported data on metastases, 9 [14, 26, 34, 35, 38, 39, 42, 43, 46] reported data on central nervous system (CNS) metastases, and 5 [14, 26, 31, 34, 42] reported data on visceral, bone or other metastases.”
Background
Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
Xu, C., Zhong, W., Zhou, Q. H., Zhang, X., Yang, J., & Wu, Y.-L. L. C. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12382 · Cited by 8
Self-citation
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
Pang, L., Zhuang, W., Chen, Z., Liao, J., Li, M.-D., Zhang, L., Fang, W., & Zhang, Y. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7092 · Cited by 7
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
“[275] A phase 2 trial demonstrated that osimertinib plus chemotherapy as a second-line treatment did not extend median PFS compared to osimertinib monotherapy in EGFR muta-tion-positive NSCLC patients who experienced disease progression with the emergence of EGFR T790M resistance mutation during…”
Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data
Lou, N., Cui, X., Lin, X., Gao, R., Xu, C., Qiao, N., Jiang, J., Wang, L., Wang, L., Wang, S., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-737 · Cited by 7
“Previous studies have indicated that only 70% of patients with EGFR -positive mutation will respond to EGFR-TKI drugs (2,3).”
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation
Zhang, L., Qi, Y., Xing, K., Song, Q., Zhang, P., & Wu, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6499 · Cited by 7
“Other studies found that intercalating gefitinib into chemotherapy compared to chemotherapy alone could prolong PFS and overall survival (OS) (9-11).”
Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer
Zhang, X., Zhang, M., Du, X., Zhang, G., Niu, Y., Wei, C., Guo, L., Shi, C., Liu, H., & Wang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1331138 · Cited by 7
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee, S. J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.020 · Cited by 7
Self-citation
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Ng, T. L., & Camidge, D. R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.73 · Cited by 7
Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
Li, Y., Liu, Y., Ying, X., Zhou, H., Wang, Z., Wu, S., Yan, J., Jing, Y., & Yang, Y. (2017) · Biotechnology Progress · doi:10.1002/btpr.2564 · Cited by 7
“The IMPRESS III clinical trial [23] indicated that continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong progression-free survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment.”
BackgroundSelf-citation
Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma
Yazdi, M. H., Faramarzi, M. A., Nikfar, S., & Abdollahi, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.088 · Cited by 7
Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
Deng, H., Lin, X., Xie, X., Yang, Y., Wang, L., Wu, J., Liu, M., Xie, Z., Qin, Y., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700023 · Cited by 6
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
Saw, S. P. L., Low, Y. F., Lai, G. G. Y., Chan, L. L., Wong, W. K. Y., Tsui, G., Chen, O. H., Seet, A. O. L., Tan, W. C., Tan, A. C., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107856 · Cited by 6
Self-citation
W‘ALK’ Into the Next Stage
Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.005 · Cited by 6
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
Salgia, R., Mambetsariev, I., Tan, T., Schwer, A. L., Pearlstein, D. P., Chehabi, H. H., Baroz, A. R., Fricke, J., Pharaon, R. R., Romo, H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061884 · Cited by 6
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
Yamada, Y., Imai, H., Sugiyama, T., Minemura, H., Kanazawa, K., Kasai, T., Minato, K., Kaira, K., & Kaburagi, T. (2021) · Medicina · doi:10.3390/medicina57090929 · Cited by 6
“Continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong PFS in patients who received platinum-based doublet chemotherapy as subsequent line of treatment [41].”
Background
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
Xu, Z., Hao, X., Wang, Q., Wang, J., Yang, K., Wang, S., Teng, F., Li, J., & Xing, P. (2022) · Cancer Management and Research · doi:10.2147/cmar.s346173 · Cited by 5
Self-citation
Anlotinib plus chemotherapy for T790M ‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs : A multicenter phase 1b/2 trial
Li, J., Tian, Y., Zheng, M., Ge, J., Zhang, J., Kong, D., Chen, M., & Yu, P. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14713 · Cited by 6
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non‑small cell lung cancer
Guan, J., Xiao, N., Qiu, C., Li, Q., Chen, M., Zhang, Y., Dai, Y., Li, L., Zhang, Y., Yang, M. Y., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9652 · Cited by 6
“In the present study, EGFR mutation status was significantly associated with sex, smoking history, histopathology, tumor grade and clinical stage, which was also verified by previous studies (22,23).”
Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR ‐mutated non‐small cell lung cancer patients with T790M ‐negative or unidentified mutation
Nishimura, T., Okano, T., Naito, M., Iwanaka, S., Ohiwa, A., Sakakura, Y., Yasuma, T., Fujimoto, H., D’Alessandro‐Gabazza, C. N., Oomoto, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13870 · Cited by 6
Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non–Small-Cell Lung Cancer
Hendriks, L. E. L., & Remón, J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01830 · Cited by 6
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC
van Doorn-Khosrovani, S. B. V. W., Badrising, S. K., & Burgers, S. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2314600 · Cited by 6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi, F., Shrestha, N., Liu, T. F. D., Foord, T. H., Heesen, P., Booth, S. W., Dodwell, D. J., Lord, S., Yeoh, K., & Blagden, S. P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014872.pub2 · Cited by 8
The Landscape and Management of Brain Parenchymal and Leptomeningeal Metastases in EGFR Mutated Non-Small Cell Lung Cancer
Hyak, J. M., & Rashdan, S. (2025) · Cancers · doi:10.3390/cancers17152434 · Cited by 5
“This is in contrast to the IMPRESS trial, where the addition of chemotherapy to gefitinib after progression on gefitinib alone did not improve PFS and led to worse overall survival, though this may just illustrate the limitations of first-generation TKIs [55,56].”
The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation
Sung, W. J., Kim, D., Zhu, A., Cho, N., Yoo, H. M., Noh, J. H., Kim, K. M., Lee, H., & Hong, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1050758 · Cited by 5
“However, the combination therapies also have limitations for tumors with EGFR-TKI-resistant patients in clinical trials in those with previous experience with TKIs (Laurila and Koivunen, 2015; Soria et al., 2015; Mok et al., 2017).”
Result
Postprogression Prolongation of Survival inEGFR-Mutated Lung Cancer
Gandara, D. R., Redman, M. W., & Hirsch, F. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4920 · Cited by 5
Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors
Mohammed, N., Zhou, R., & Xiong, Z. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210228 · Cited by 5
Green Synthesis and Anticancer Evaluation of Novel Chrysin Hydrazone Derivatives
Pouramiri, B., Seyedhosseini, S. R., Nematollahi, M. H., Faramarz, S., Seyedi, F., & Ayati, A. (2021) · Polycyclic aromatic compounds · doi:10.1080/10406638.2021.2011753 · Cited by 5
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations
Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group, Imai, H., Minemura, H., Sugiyama, T., Yamada, Y., Kaira, K., Kanazawa, K., Kasai, T., Kaburagi, T., & Minato, K. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3596-6 · Cited by 5
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III–IV lung squamous cell carcinoma
Song, J., Tian, J., Zhang, L., Qu, X., Qian, W., Zheng, B., Zhang, L., Zhao, J., Niu, M., Zhou, M., et al. (2019) · European Radiology · doi:10.1007/s00330-018-5912-2 · Cited by 5
Self-citation
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
Schmid, S., Stewart, E., Martins-Filho, S. N., Cabanero, M., Wang, A., Bao, H., Wu, X., Patel, D., Chen, Z., Law, J. H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.03.009 · Cited by 5
Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
Zhang, Y., Wang, J., Yu, Z., Ge, H., Zhang, L., & Feng, L. (2020) · Clinical and Translational Science · doi:10.1111/cts.12951 · Cited by 5
Self-citation
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients
Smith, T. J., Hanna, N. H., Johnson, D. H., Baker, S., Biermann, W. A., Brahmer, J. R., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I. A., et al. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.027367 · Cited by 5
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer
Takamori, S., Haratake, N., Bhattacharya, A., Kikutake, C., Ozawa, H., Shigeta, K., Nakashoji, A., Isozaki, H., Shimokawa, M., Suyama, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02482-7 · Cited by 4
Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series
Shimbu, K., Hisakane, K., Kadoma, N., Nishima, S., Atsumi, K., Seike, M., & Hirose, T. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s475836 · Cited by 4
Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
Xu, Z., Teng, F., Hao, X., Li, J., & Xing, P. (2022) · Cancer Management and Research · doi:10.2147/cmar.s363446 · Cited by 4
“Therefore, continuation of EGFR-TKI was not recommended for patients who received platinum-based chemotherapy after EGFR-TKI progression.(10,11) A preclinical experiment established that bevacizumab suppressed tumor regrowth even in erlotinib-refractory phase to prolong the anti-tumor effect in mouse xenograft models.”
Background
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
Okuma, Y., Nomura, S., Ninomiya, K., Gyotoku, H., Murakami, S., Kogure, Y., Harada, D., Okishio, K., Okamoto, H., & Goto, Y. (2023) · Future Oncology · doi:10.2217/fon-2022-1128 · Cited by 4

Authors: Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., Ponce, S., Lee, D. H., Liu, Y., Yoh, K., Zhou, J.-Y., Shi, X., Webster, A., Jiang, H., & Mok, T. S. K.
Affiliations: Institut Gustave Roussy (FR)
Guangdong General Hospital (CN)
Kindai University (JP)
Asan Medical Center (KR)
National Taiwan University (TW)
Samsung Medical Center (KR)
Peking University Cancer Hospital (CN)
NHO Kinki Chuo Chest Medical Center (JP)
Hospital Universitario 12 De Octubre (ES)
First Hospital of China Medical University (CN)
National Cancer Center Hospital East (JP)
AstraZeneca (United Kingdom) (GB)
Chinese University of Hong Kong (HK)
Corresponding author: Mok, Tony S K
ORCID: Soria, Jean-Charles
Wu, Yi-Long
Nakagawa, Kazuhiko
Yang, Jin-Ji
Ahn, Myung-Ju
Wang, Jie
Yang, James Chih-Hsin
Atagi, Shinji
Ponce, Santiago
Liu, Yunpeng
Yoh, Kiyotaka
Shi, Xiaojin
Jiang, Haiyi
Mok, Tony S K
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2015-08
Volume: 16
Issue: 8
Pages: 990-998
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(15)00121-7
OpenAlex: W2152481222
Semantic Scholar: 8a3893572a340f3e2e3dc31440e3947d55eb0893
Cited by: 413
References: 30
Citations by year: 2026: 13 · 2025: 22 · 2024: 21 · 2023: 28 · 2022: 28 · 2021: 34 · 2020: 36 · 2019: 35 · 2018: 53 · 2017: 66 · 2016: 61 · 2015: 15
FWCI: 51.33
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: gefitinib, EGFR mutation, non-small cell lung cancer, acquired resistance, EGFR tyrosine kinase inhibitors, cisplatin, pemetrexed, platinum-based chemotherapy, progression-free survival, second-line therapy, treatment safety, overall survival, quality of life, patient-reported outcomes, adverse events
MeSH terms: Pemetrexed, Gefitinib, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Mutation, Phenotype, Prospective Studies, Quinazolines, Time Factors, Biomarkers, Tumor, Proportional Hazards Models, Treatment Outcome, Disease Progression, Disease-Free Survival, Genetic Predisposition to Disease, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks